SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis.

ABSTRACT: Over the last decade, the Janus kinase (JAK) 1/2 inhibitor ruxolitinib has become widely established as the cornerstone of pharmacologic therapy for most patients with myelofibrosis (MF), providing dramatic and durable benefits in terms of splenomegaly and symptoms, and prolonging survival. Ruxolitinib does not address all aspects of the disease, however; notably cytopenias, and its ability to modify the underlying biology of the disease remains in question. Furthermore, patients eventually lose response to ruxolitinib. Multiple groups have reported the median overall survival of MF patients after ruxolitinib discontinuation to be 13 to 14 months. While consensus criteria only recognize splenic and blast progression as "progressive disease" in patients with MF, disease progression can occu

SUBMITTER: Bose P 

PROVIDER: S-EPMC8565615 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature